Compare JPMorgan Ultra Short Income ETF (JPST) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Moderna, Inc. — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.3 (market cap $42.37B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Moderna, Inc. for 59 Days on average.
| JPST | MRNA | |
|---|---|---|
Market Cap | $42.37B | $78.65B |
Volume | 7,889,185 | 37,373,437 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $203.46 |
52-Week Low | $50.22 | $22.36 |
Typical Hold Time | 47 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.30 with minimal daily movement, showing stability typical of ultra-short bond funds. Technical indicators signal bearish momentum with moving averages in sell territory, though oversold RSI levels suggest potential near-term stabilization. Recent news highlights institutional position adjustments and growing investor interest in cash-alternative ETFs amid rising rate expectations.
The ETF faces headwinds from active management costs and competitive pressure from similar funds, though demand for ultrashort duration assets provides support. Key risks include interest rate sensitivity and fund flow volatility, while institutional ownership changes indicate mixed sentiment among professional investors.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
